TNFA (Tumor Necrosis Factor-Alpha)

This study aimed to investigate the combined use of ACD and TP (paclitaxel and cisplatin) against non-small cell lung cancer (NSCLC) in a orthotopic mouse model. In conclusion, the combination of ACD plus TP demonstrated potent anti-tumor and immunomodulation effects against NSCLC in association with reduced Treg activity and increased CD8+ T cell infiltration. Our study provides compelling preclinical evidence supporting ACD as an immunomodulatory adjunct to conventional NSCLC therapies.

The questionnaire-based approach proved effective for identifying older women at risk for vitamin D deficiency. Combined with serum vitamin D status, it was associated with functional impairment and an unfavorable myokine-inflammatory profile. This supports the implementation of community screening to identify high-risk individuals for further testing and targeted lifestyle interventions.

These integrated results suggest a potential mechanism by which PPP alleviates influenza-driven lung injury through the modulation of the gut microbiota-host metabolism axis. This study provides correlative evidence supporting the involvement of the gut-lung axis in PPP's protective effects, offering theoretical insights for future antiviral research.

In both in vitro and in vivo experiments, Jionoside B1 significantly suppressed lipid synthesis and attenuated tumor growth. This study systematically elucidates the mechanism by which low-dose TNF-α regulates lipid metabolism and promotes GBM malignant progression via the TRAF2-FASN axis, providing not only new insights into the "double-edged sword" role of TNF-α in the tumor microenvironment but also a potential novel therapeutic strategy for targeting this pathway in GBM treatment.

Resveratrol mitigates sevoflurane-induced OPCs differentiation impairments and hypomyelination via inhibiting microglial activation, which may be mediated by Nrf2/HO-1 signalling.

Collectively, BHB lowers pro-inflammatory monocyte marker expression ex vivo and dose-dependently reduces TNF-α production in LPS-stimulated whole blood and monocyte cultures. These effects appear to be partly mediated by acidification of the extracellular environment.

Excessive removal of LNs might exert adverse impact on physical sensitivity to immunochemotherapy. Personalized lymph node management should be adopted for selected node-negative disease.

The outcomes back up the traditional use of bene gum as an effective wound healer.

Functional assays revealed that LUZP1 knockdown impaired migration, invasion, invadopodia formation and epithelial‑mesenchymal transition, while enhancing sensitivity to docetaxel and cisplatin. Immunohistochemical analysis of clinical samples demonstrated that high LUZP1 expression was associated with shorter overall and progression‑free survival. Collectively, these findings identify LUZP1 as a novel NF‑κB‑regulated effector that promotes metastasis and chemoresistance and highlight its potential as a prognostic biomarker and therapeutic target in HNSCC.

These findings collectively suggest that d-pinitol promotes osteoblast differentiation under inflammatory stress by inducing ST6Gal-1 expression, thereby suppressing the CREBH-Smurf1 signaling axis and ER stress pathways. Our results highlight the potential therapeutic implications of d-pinitol in managing inflammatory bone diseases.

This study not only establishes a causal relationship between SS and NHL but, more importantly, identifies circulating TNFRSF9 as a key functional biomarker linking autoimmunity to lymphomagenesis. This finding suggests that circulating TNFRSF9 levels emerge as a candidate biomarker worthy of further investigation. Future prospective clinical studies are needed to correlate serum TNFRSF9 levels with lymphoma development. Key Points • First genetic evidence establishing a causal link between Sjögren's syndrome and increased risk of non-Hodgkin lymphoma using Mendelian randomization. • TNFRSF9 is identified as a key inflammatory mediator, upregulated by Sjögren's syndrome and independently driving lymphoma risk. • Mediation analysis quantifies that TNFRSF9 accounts for approximately 18% of the total causal effect of Sjögren's syndrome on lymphoma. • A novel biomarker and potential therapeutic target, circulating TNFRSF9 may enable risk stratification in Sjögren's syndrome patients.

Our study demonstrated that MRI semantic features, including ependymal extension and CET crossing the midline, can serve as prognostic indicators for patients with GBM. Additionally, several selected MRI features were found to be associated with specific biological pathways, potentially informing treatment decisions based on these distinctive semantic characteristics of GBM.